Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants

Kumar, Anita J.; Kim, Soyoung; Hemmer, Michael; Arora, Mukta; Spellman, Stephen R.; Pidala, Joseph; Couriel, Daniel R.; Alousi, Amin M.; Aljurf, Mahmoud; Cahn, Jean Yves; Cairo, Mitchell S.; Cutler, Corey; Farhan, Shatha; Gergis, Usama; Hale, Gregory A.; Hashmi, Shahrukh K.; Inamoto, Yoshihiro; Kamble, Rammurti T.; Kharfan‐Dabaja, Mohamed A.; MacMillan, Margaret L.; Marks, David I.; Nakasone, Hideki; Norkin, Maxim; Qayed, Muna; Ringdén, Olle; Schouten, Harry C.; Schultz, Kirk R.; Solh, Melhem; Teshima, Takanori; Urbano-Ispizúa, Álvaro; Verdonck, Leo F.; Gale, Robert Peter; Hamilton, Betty K.; Majhail, Navneet S.; Loren, Alison W.

doi:10.1182/bloodadvances.2017013052

Cited by 13 publications

(7 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following four grafting procedures over a six-month period, the facial ulcers epithelialised and remained closed for the duration of the eight-month follow-up [ 56 ]. Graft versus host disease was not evident and may have been reduced owing to the use of keratinocytes from a related donor [ 57 ]. In another study, allogeneic keratinocyte sheets were used to treat a neonate with JEB [ 31 ].…”

Section: Tesss For Ebmentioning

confidence: 99%

Epidermolysis Bullosa: A Review of the Tissue-Engineered Skin Substitutes Used to Treat Wounds

et al. 2022

View full text Add to dashboard Cite

Skin wound healing is a crucial process for regenerating healthy skin and avoiding the undesired consequences associated with open skin wounds. For epidermolysis bullosa (EB), a debilitating group of fragile skin disorders currently without a cure, skin blistering can often be severe and heal poorly, increasing susceptibility to life-threatening complications. To prevent these, investigational therapies have been exploring the use of tissue-engineered skin substitutes (TESSs) aimed at replacing damaged skin and promoting long-term wound closure. These products have either been developed in house or commercially sourced and are composed of allogeneic or autologous human skin cells, often with some form of bioscaffolding. They can be broadly classified based on their cellular composition: keratinocytes (epidermal substitutes), fibroblasts (dermal substitutes) or a combination of both (composite substitutes). Encouraging long-term wound healing has been achieved with epidermal substitutes. However, these substitutes have not demonstrated the same efficacy for all patients, which may be due to the molecular heterogeneity observed between EB subtypes. Autologous composite TESSs, which more closely resemble native human skin, are therefore being investigated and may hold promise for treating an extended range of patients. Additionally, future TESSs for EB are focused on using gene-corrected patient skin cells, which have already demonstrated remarkable long-term wound healing capabilities. In this review, we provide an overview of the different TESSs that have been investigated in clinical studies to treat patients with EB, as well as their long-term wound healing results. Where available, we describe the methods used to develop these products to inform future efforts in this field.

show abstract

Section: Tesss For Ebmentioning

confidence: 99%

Epidermolysis Bullosa: A Review of the Tissue-Engineered Skin Substitutes Used to Treat Wounds

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In the study by Brandon et al the median time from procedure to attaining the spirometric definition for bronchiolitis obliterans syndrome was 439 days (range 274-1690). While most previously identified risk factors were not significantly associated with bronchiolitis obliterans, not being Caucasian (p = 0.014), lower circulating IgG levels (p = 0.010) and the presence of cGVHD (p \ 0.001) were Males make better donors than previously pregnant females [16] (b) Graft source/characteristics Umbilical cord blood is associated with less risk due to immunological immaturity of T cells. [17,18] PBSCT associated with higher risk than BMT [19] (c) Stem cells manipulation with T cell depleted better than T cell replete [20] (e) Cytomegalovirus status [21] Secondary malignancies (a) Prior therapy: chemotherapy/radiotherapy [22] (b) Conditioning regimen: myelo ablative/reduced intensity conditioning [22] Organ toxicity (a) Prior therapy: chemotherapy/radiotherapy [22].…”

Section: Bronchiolitis Obliterans (Bo)mentioning

confidence: 99%

Late Complications of Allogenic Stem Cells Transplantation in Leukaemia

Kanagasundram

Amini

2018

Tissue Eng Regen Med

View full text Add to dashboard Cite

BACKGROUND: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) can cure leukaemia. However, long term complications of post transplantation interfere with the patients' full recovery. The objective of this review was to identify the various long term complications and to assess their individual prevalences. METHODS: Electronic databases including PubMed, Google Scholar and Cochrane were searched for years 2004-2017. The keywords used were leukaemia, allogenic stem cell transplantation, prevalence, side effects, long term, delayed, adverse effects, complications and outcome. RESULTS: A total of ten articles were included for analysis. There were 5 prospective studies, 3 retrospective studies and 2 cross sectional studies. A total of 40,069 patients, (20,189 males and 17,191 females) participated in these 10 studies. The gender of 2689 patients were not disclosed. Most common late complications and prevalence were chronic graft versus host disease (43% at 5 years post HSCT), secondary tumor (21% at 20 years post HSCT), hypothyroidism (11% at 15 years), bronchiolitis obliterans (9.7% at 122 days), cardiovascular disease (7.5% at 15 years) and avascular necrosis (5.4% at 10 years). The prevalence of azoospermia was 71.1% and depression, 18%. For the latter two conditions no time limit was available. Follow up duration ranged from 2 years till 30 years post HSCT. CONCLUSION: While allogenic stem cell transplantation is an effective cure for leukaemia, the procedure is associated with complications that can have their onset many years after the procedure.

show abstract

“…Acute GvHD occurs in 40%–50% of patients receiving allo-HSCT, which makes aGvHD a major risk factor for developing cGvHD ( 20 ). Other known risk factors include specific diseases, such as chronic myeloid leukemia (CML), age (older patients are more prone to cGvHD), use of mismatched or unrelated donors compared to matched sibling transplants, use of peripheral blood stem cells instead of bone marrow stem cells as a graft source, and sex mismatch between recipients (especially male) and donor (especially female) ( 21 , 22 ). This review therefore, provides the current knowledge on the emerging therapies for cGvHD, with particular emphasis on TKIs, JAK1/JAK2, and proteasome inhibitors that are now ready for entering into clinical practice.…”

Section: Introductionmentioning

confidence: 99%

New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions

et al. 2020

View full text Add to dashboard Cite

Chronic graft-versus-host disease (cGvHD) is a severe complication of allogeneic hematopoietic stem cell transplantation that affects various organs leading to a reduced quality of life. The condition often requires enduring immunosuppressive therapy, which can also lead to the development of severe side effects. Several approaches including small molecule inhibitors, antibodies, cytokines, and cellular therapies are now being developed for the treatment of cGvHD, and some of these therapies have been or are currently tested in clinical trials. In this review, we discuss these emerging therapies with particular emphasis on tyrosine kinase inhibitors (TKIs). TKIs are a class of compounds that inhibits tyrosine kinases, thereby preventing the dissemination of growth signals and activation of key cellular proteins that are involved in cell growth and division. Because they have been shown to inhibit key kinases in both B cells and T cells that are involved in the pathophysiology of cGvHD, TKIs present new promising therapeutic approaches. Ibrutinib, a Bruton tyrosine kinase (Btk) inhibitor, has recently been approved by the Food and Drug Administration (FDA) in the United States for the treatment of adult patients with cGvHD after failure of first-line of systemic therapy. Also, Janus Associated Kinases (JAK1 and JAK2) inhibitors, such as itacitinib (JAK1) and ruxolitinib (JAK1 and 2), are promising in the treatment of cGvHD. Herein, we present the current status and future directions of the use of these new drugs with particular spotlight on their targeting of specific intracellular signal transduction cascades important for cGvHD, in order to shed some light on their possible mode of actions.

show abstract

Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants

Abstract: Key Points Compared with parous female sibling donors, male URDs confer more aGVHD in all patients and more cGVHD in females. There was no difference in survival, relapse, or transplant mortality between recipients of parous female sibling or male URD grafts.

Cited by 13 publications

References 35 publications

Epidermolysis Bullosa: A Review of the Tissue-Engineered Skin Substitutes Used to Treat Wounds

Epidermolysis Bullosa: A Review of the Tissue-Engineered Skin Substitutes Used to Treat Wounds

Late Complications of Allogenic Stem Cells Transplantation in Leukaemia

New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions

Contact Info

Product

Resources

About